CASE OF SUCCESSFUL ADMINISTRATION OF TENOFOVIR IN PATIENTS WITH CHRONIC HDV-INFECTION WITH SEVERE FIBROSIS
DOI:
https://doi.org/10.11603/1681-2727.2015.4.5526Abstract
SUMMARY. Chronic HDV-infection most often occurs in severe forms of hepatitis with rapid formation of liver cirrhosis and development of liver failure, but the effective treatment is at an early stage of development. The possibility of antiviral therapy significantly limited if there are contraindications, especially in distinct liver fibrosis. The article is an example of effective use of tenofovir in patients with chronic HDV-infection with fibrosis F4.
Key words: chronic hepatitis D, treatment, tenofovir.
References
Література
Heidrich B. Treatment options for hepatitis delta virus infection / B. Heidrich, M.P. Manns, H. Wedemeyer // Curr Infect. Dis. Rep. – 2013. – Vol. 15, N 1. – P. 31-38.
Delta-infection and suppression of hepatitis B virus replication in chronic HBsAg carriers / [K. Krogsgaard, P. Kryger, J. Aldershvile et al.] // Hepatology. – 1987. – N 7. – P. 42-45.
Acute and chronic hepatitis delta virus infection: direct or indirect effect on hepatitis B virus replication? / [P. Farci, P. Karayiannis, M.E. Lai, et al.] // J. Med. Virol. – 1988. – N 26. – P. 279-288.
Porokhnytskyi V.H. Virusni hepatyty / V.H. Porokhnytskyi, V.S. Topolnytskyi. – K.: Knyha-plius, 2010. – 480 s.
Uchaikyn V.F. Ynfektsyonnaia hepatolohyia: rukovodstvo dlia vrachei / V.F. Uchaikyn, T.V. Cherednychenko, A.V. Smyrnov. – M. : HEOTAR-Medya, 2012. – 640 s.
Hepatitis B Virus Replication in Acute Hepatitis B. Virus-hepatitis Delta Coinfection and Acute Hepatitis Delta Superinfection / [I.J. Genescal, R. Jardi, M. Butti et al.] // Hepatology. – 1987. – Vol. 7, N 3. – P. 569-572.
Influence of delta infection on severity of hepatitis B / [A. Smedile, P. Farci, G. Verme et al.] // Lancet. – 1982. – Vol. 2, N 8305. – P. 945-947.
Chronic hepatitis incarriers of hepatitis B surface antigen with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment / [M. Rizzetto, G. Verme, S. Recchia et al.] // Ann. Intern. Med. – 1983. – Vol. 98, N 4. – P. 437-441.
Shyff Yu.R. Bolezny pecheny po Shyffu / Yu.R. Shyff, M.F. Sorrel, U.S. Mэddrei: per. s anhl. V.T. Yvashkyna, E.A. Klymovoi, Y.H. Nykytyna, E.N. Shyrokovoi. – M.: HEOTAR-Medya, 2010. – 398 s.
Maraolo A. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa / A. Maraolo, F. Minervini, G. Tosone // Aliment Pharmacol The. – 2015. – N 41. – P. 595.
Long-term therapy of chronic delta hepatitis with peginterferon alfa / [T. Heller, Y. Rotman, C. Koh et al.] // Aliment Pharmacol The. – 2014. – N 40. – P. 93-104.
Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy / [D.T. Lau, D.E. Kleiner, Y. Park et al.] // Gastroenterology. – 1999. – N 117. – P. 1229-1233.
Understanding hepatitis virus dynamics and antiviral efficacy of the prenylation inhibitor lonafarnib / [L. Canini, C. Koh, S.J. Cotler et al.] // Hepatology. – 2014. – N 60. – P. 32A-91A.
Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans [C. Koh, C. Yurdaydin, S. Cooper et al.] // Hepatology. – 2014. – N 60. – 92A-196A.
A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B / [P. Bogomolov, N. Voronkova, L. Allweiss et al.] // Hepatology. – 2014. – N 60. – P. 1267A-1290A.
Wedemeyer H. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead / H. Wedemeyer, M.P. Manns. – Nat. Rev. Gastroenterol. Hepatol. – 2010. – N 7. – P. 31-40.
Ynfektsyonnye bolezny. Farmakoterapyia / Pod red. L.V. Moroz. – K.: Doktor-Medya, 2011. – 440 s.
Abdurakhmanov D.T. Vozmozhen ly rehress fybroza pecheny pry khronycheskom vyrusnom hepatyte? / D.T. Abdurakhmanov, M.V. Severov // Klynycheskaia farmakolohyia y terapyia. –2011. – № 20 (1). – S. 21-25.
Downloads
Published
How to Cite
Issue
Section
License
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
